K Raja Reddy

This inventor holds 32 USPTO granted patents and 3 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Phosphorus-Containing Compounds. Top assignees: Metabasis Therapeutics, Inc., Sankyo Company, Limited. Active years: 2000-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: K Raja Reddy. Retrieved from https://idiyas.com/inventor/k-raja-reddy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 32 (Patent Applications = 3)

% Patents Active = 71.9

CIPO Patents = 5

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 4.1

ph-index = 11

Forward Citations = 766(Granted Patents)

Company Filing History:

31 out of 64

Metabasis Therapeutics, Inc.

patents

1 out of 613

Sankyo Company, Limited

patents

Years Active: 2000-2020

Loading Chart...

Areas of Expertise:

Diacylglycerol O-Acyltransferase

Glucagon Receptor Antagonists

Nucleoside Prodrugs

Phosphorus-Containing Prodrugs

Fructose-1,6-Bisphosphatase Inhibitors

Cyclic Phosphate Diesters

Aryl Fructose-1,6-Bisphosphatase

Purine Inhibitors

Heteroaromatic Compounds

Benzimidazole Inhibitors

Indole Inhibitors

Liver Specific Drug Delivery

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10709718 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2020-07-14),

2. 10034891 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2018-07-31),

3. 9340566 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2016-05-17),

4. 8962618 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2015-02-24),

5. 8710236 - Antagonists of the glucagon receptor (2014-04-29),

6. 8664195 - Phosphorus-containing prodrugs (2014-03-04),

7. 8080536 - Phosphorus-containing prodrugs (2011-12-20),

8. 8063025 - Nucleoside prodrugs and uses thereof (2011-11-22),

9. 7816345 - Phosphorus-containing prodrugs (2010-10-19),

10. 7666855 - 2'-C-methyl nucleoside derivatives (2010-02-23),

11. 7498320 - Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs (2009-03-03),

12. 7371739 - Aryl fructose-1,6-bisphosphatase inhibitors (2008-05-13),

13. 7351399 - Prodrugs for phosphorus-containing compounds (2008-04-01),

14. 7312219 - Heteroaromatic inhibitors of fructose 1,6-bisphosphatase (2007-12-25),

15. 7303739 - Prodrugs for liver specific drug delivery (2007-12-04),

Title: **K Raja Reddy: Innovator in Pharmaceutical Patents**

Introduction

K Raja Reddy, located in San Diego, California, is a prominent inventor known for his significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio encompassing 32 patents, Raja Reddy has made substantial advancements in the treatment of metabolic disorders and conditions related to hyperlipidemia.

Latest Patents

Among his notable inventions, K Raja Reddy has developed inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1), which are crucial in treating hyperlipidemias. His first patent relates to the use of fused bicyclic heterocyclic adducts of thiohydroxy pyridines or pyrimidines as DGAT-1 inhibitors, targeting various diseases associated with lipid metabolism. These inhibitors aim to ameliorate conditions such as high postprandial triglycerides, diet-related hypertriglyceridemia, and cardiovascular risks linked to excessive triglycerides. Additionally, they show potential for combating insulin resistance and glucose intolerance, particularly in patients who are overweight, diabetic, or suffering from glucose metabolic disorders like Syndrome X and polycystic ovary disease.

Another breakthrough patent from Raja Reddy describes compounds that can also act as inhibitors of DGAT-1, identified by the formula Q-G-G-G-G-Z. This innovation echoes the aim of providing therapeutic solutions for similar health issues, further establishing his authority in the domain of metabolic disease treatment.

Career Highlights

Throughout his career, K Raja Reddy has been associated with notable companies within the pharmaceutical industry, such as Metabasis Therapeutics, Inc. and Sankyo Company, Limited. His work has significantly contributed to the understanding and treatment of lipid metabolism disorders.

Collaborations

In his journey, Raja has collaborated with esteemed professionals including Mark D. Erion and Qun Dang. These collaborations have enriched his research and led to impactful innovations in the field.

Conclusion

K Raja Reddy's extensive patent portfolio and collaborative efforts emphasize his role as a leading inventor and innovator in pharmaceutical sciences. His work on DGAT-1 inhibitors not only showcases his expertise but also highlights the potential for innovative treatments for complex metabolic disorders.

Profile summary based on public USPTO records.